Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Group 1 - The core point of the article highlights the recent performance of Dongfang Biological, which saw a 5.15% increase in stock price, reaching 26.13 yuan per share, with a total market capitalization of 5.268 billion yuan [1] - Dongfang Biological, established on December 1, 2005, specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents [1] - The company has a trading volume of 1.05 billion yuan and a turnover rate of 2.01% [1] Group 2 - From the perspective of major shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) reduced its holdings by 1.7001 million shares in the third quarter, now holding 2.8 million shares, which represents 1.39% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.2% and a one-year return of 8.7%, ranking 5437 out of 8154 and 6141 out of 8046 respectively [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 69 days, with the fund's total asset size at 5.957 billion yuan [3] Group 3 - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has Dongfang Biological as its tenth largest holding, accounting for 2.98% of the fund's net value [4] - The fund's floating profit from its investment in Dongfang Biological is approximately 3.584 million yuan [4]

Group 1 - Oriental Bio (688298.SH) reported its Q3 2025 results on October 31, 2025, with a total of 7 institutional investors holding A-shares, amounting to 104 million shares, which represents 51.44% of the total share capital [1] - The institutional investors include companies such as Anji Fulanglai Import and Export Trade Co., Ltd., Fangs Holdings Limited Liability Company, and several funds from China Industrial Bank and China Merchants Bank [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 1.23 percentage points [1] Group 2 - In the public fund sector, one fund, the Medical Device ETF, increased its holdings by 0.21% compared to the previous period [2] - One fund, the Rongtong Health Industry Flexible Allocation Mixed A/B, reduced its holdings by 0.84% compared to the previous quarter [2] - A total of 63 public funds did not disclose their holdings this period, including funds like Yuanxin Yongfeng Ju You A and Rongtong Value Growth Mixed A [2]

Core Viewpoint - On October 30, 2025, the company will hold the 15th meeting of the third board of directors to review the proposal regarding the confirmation of the audit committee members and the nomination of the convener [2] Group 1 - The company announced the date for the upcoming board meeting [2] - The agenda includes the confirmation of audit committee members [2] - The proposal also involves the nomination of the convener for the audit committee [2]

Core Viewpoint - Dongfang Biological announced the appointment of Mr. Xi Shichang as the company's financial officer on the evening of October 30 [2] Group 1 - The company has officially appointed a new financial officer, indicating a potential shift in financial strategy or management [2]

Core Viewpoint - Dongfang Biological (688298.SH) reported a total operating revenue of 672 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.16% [1] - The net profit attributable to shareholders of the parent company was -213 million yuan, which represents a reduction in losses by 49.52 million yuan compared to the same period last year [1] - The basic earnings per share stood at -1.1 yuan [1] Financial Performance - Total operating revenue for the first three quarters reached 672 million yuan, marking a 2.16% increase year-on-year [1] - The net profit attributable to the parent company's shareholders was -213 million yuan, indicating a significant reduction in losses by 49.52 million yuan compared to the previous year [1] - Basic earnings per share were reported at -1.1 yuan [1]

关于财务负责人辞职暨聘任财务负责人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688298 证券简称：东方生物 公告编号：2025-056 浙江东方基因生物制品股份有限公司 | 姓名 | 离任职务 | 离任时间 | | | | 是否继续在 离任原因 | | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 原定任期 | | 上市公司及 | 具体职务 | 未履行完 | | | | | | 到期日 | | 其控股子公 | （如适用） | 毕的公开 | | | | | | | | 司任职 | | 承诺 | | 俞锦洪 | 财务负责人 | 2025 10 | 年 | 2026 | 年 5 | 工作分工 是 | 副总经理 | 是 | | | | 月 30 | 日 | 月 31 日 | | 调整原因 | | | 浙江东方基因生物制品股份有限公司（以下简称"公司"）于近日收到副总 经理、财务负责人俞锦洪先生的 ...

公司于 2025 年 10 月 30 日召开第三届董事会第十五次会议，审议通过了《关 于确认审计委员会委员及推选召集人的议案》，现将相关情况公告如下： 根据《公司法》《上市公司章程指引》等相关规定，公司董事会审计委员会 行使《公司法》规定的监事会职权，为进一步完善公司治理结构，保障规范运作， 并结合公司实际情况，确认公司第三届董事会审计委员会成员为：张红英女士、 王晓燕女士及陈虞女士，并推举张红英女士为公司第三届董事会审计委员会召集 人，任主任委员，任期至公司第三届董事会任期届满之日止。 证券代码：688298 证券简称：东方生物 公告编号：2025-055 浙江东方基因生物制品股份有限公司 关于确认审计委员会成员并推选召集人的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 9 月 15 日，浙江东方基因生物制品股份有限公司（以下简称"公司"） 召开 2025 年第一次临时股东大会，审议通过关于《关于取消监事会并修订<公司 章程>的议案》，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上海证券 ...

本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 证券代码：688298 证券简称：东方生物 公告编号：2025-058 浙江东方基因生物制品股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江东方基因生物制品股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 12 日 （星 期三） 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进 行交流。 一、 说明会类型 本次投资者说明会召开后，投资者可以通过上证路演中心（https://roads how.sseinfo.com/）查看本次投资者 ...

第三届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届董事会第 十五次会议于 2025 年 10 月 20 日以电子邮件及通讯形式发出会议通知，于 2025 年 10 月 30 日上午 10:30 在公司会议室以现场会议加通讯表决的方式召开。会议 应出席董事 6 名，实到出席董事 6 名。会议召开符合法律法规、《公司法》及《公 司章程》的相关规定。 会议由董事长方剑秋先生主持召开，全体与会董事经认真审议和表决，形成 以下决议： 证券代码：688298 证券简称：东方生物 公告编号：2025-057 浙江东方基因生物制品股份有限公司 2、审议通过《关于确认董事会审计委员会委员及推选召集人的议案》 表决情况：本议案有效表决票 6 票，同意 6 票、反对 0 票、弃权 0 票。 经公司 2025 年第一次临时股东大会审议通过，公司不再设置监事会。同日， 公司职工代表大会选举陈虞女士为职工代表董事。根据《公司法》《上市公司章 程指引》等相关规定， ...